)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CARGO Therapeutics
CARGO Therapeutics (CRGX) investor relations material
CARGO Therapeutics has been acquired
CARGO Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Discontinued lead Phase 2 study and suspended all pipeline development, resulting in a 90% workforce reduction and major restructuring in early 2025.
Entered into a merger agreement with Concentra Biosciences in July 2025, with a cash tender offer and contingent value rights for shareholders.
If the merger is not completed, alternatives include dissolution and liquidation or other strategic transactions.
Financial highlights
Net loss of $49.9M for Q2 2025, compared to $44.3M in Q2 2024; net loss of $134.4M for the first half of 2025, up from $80.2M year-over-year.
Operating expenses rose to $52.9M in Q2 2025 from $49.3M in Q2 2024, driven by $37.1M in restructuring and impairment costs.
Cash, cash equivalents, and marketable securities totaled $252.6M as of June 30, 2025.
Accumulated deficit reached $447.1M as of June 30, 2025.
Interest income decreased to $3.3M in Q2 2025 from $5.0M in Q2 2024 due to lower average balances.
Outlook and guidance
Operating expenses expected to decrease for the remainder of 2025 due to workforce reductions and program suspensions.
Cash runway projected to support operations for at least 12 months from the financial statement issuance date.
Completion of the merger is uncertain; if not completed, the board may pursue liquidation or alternative transactions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CARGO Therapeutics
- Firi-cel demonstrates high response and durability in lymphoma, with pivotal data due in 2025.CRGX
Piper Sandler 36th Annual Healthcare Conference - Firi-cel demonstrates high durable response and safety in post-CD19 CAR-T lymphoma, with pivotal data due in 2025.CRGXJefferies London Healthcare Conference 2024
- Q3 net loss was $41.9M; cash reserves of $404.8M support operations through 2026.CRGXQ3 2024
- Q2 net loss $44.3M; $443.5M cash; $110M PIPE; pivotal study interim data in H1 2025.CRGXQ2 2024
- Firi-cel shows durable responses in R/R LBCL post-CD19 CAR T, with pivotal Phase 2 underway.CRGXCorporate Presentation
- Lead CAR T program demonstrates durable responses; $110M PIPE fuels pivotal trial and pipeline growth.CRGXJefferies 2024 Global Healthcare Conference
- Q1 2025 loss surged to $84.5M after major restructuring and program suspension.CRGXQ1 2025
- Advancing three innovative cell therapy programs with key data and milestones expected in 2024.CRGX43rd Annual J.P. Morgan Healthcare Conference 2025
- CARGO halts development, slashes workforce, and seeks a merger with $368M cash on hand.CRGXQ4 2024
CARGO Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CARGO Therapeutics Inc. is a clinical-stage biotechnology company dedicated to advancing the next generation of chimeric antigen receptor (CAR) T-cell therapies aimed at cancer treatment. The company is focused on developing transformative CAR T-cell therapies with the mission of outsmarting cancer and delivering more cures for patients globally. By addressing the limitations of currently approved cell therapies, such as limited durability, safety concerns, and unreliable supply, CARGO Therapeutics is working on engineering CAR T-cells with genetic "cargo" designed to enhance the ability to recognize and kill cancer cells.The company is headquartered in San Carlos, California, and its shares are listed on the Nasdaq.